169 related articles for article (PubMed ID: 17424980)
41. Usefulness of a breath-holding acquisition method in PET/CT for pulmonary lesions.
Yamaguchi T; Ueda O; Hara H; Sakai H; Kida T; Suzuki K; Adachi S; Ishii K
Ann Nucl Med; 2009 Jan; 23(1):65-71. PubMed ID: 19205840
[TBL] [Abstract][Full Text] [Related]
42. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
43. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
44. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis.
Perri M; Erba P; Volterrani D; Guidoccio F; Lazzeri E; Caramella D; Mariani G
AJR Am J Roentgenol; 2011 Jul; 197(1):209-16. PubMed ID: 21701032
[TBL] [Abstract][Full Text] [Related]
45. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer.
Kaira K; Oriuchi N; Shimizu K; Tominaga H; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Mori M; Endo K
J Nucl Med; 2009 Nov; 50(11):1770-6. PubMed ID: 19837768
[TBL] [Abstract][Full Text] [Related]
46. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas.
Nakamoto Y; Higashi T; Sakahara H; Tamaki N; Kogire M; Doi R; Hosotani R; Imamura M; Konishi J
Cancer; 2000 Dec; 89(12):2547-54. PubMed ID: 11135214
[TBL] [Abstract][Full Text] [Related]
47. Diagnosis of tumor in the nasal cavity and paranasal sinuses with [11C]choline PET: comparative study with 2-[18F]fluoro-2-deoxy-D-glucose (FDG) PET.
Ninomiya H; Oriuchi N; Kahn N; Higuchi T; Endo K; Takahashi K; Chikamatsu K; Kamada H; Furuya N
Ann Nucl Med; 2004 Feb; 18(1):29-34. PubMed ID: 15072181
[TBL] [Abstract][Full Text] [Related]
48. Oncological diagnosis using (11)C-choline-positron emission tomography in comparison with 2-deoxy-2-[(18)F] fluoro-D-glucose-positron emission tomography.
Tian M; Zhang H; Higuchi T; Oriuchi N; Endo K
Mol Imaging Biol; 2004; 6(3):172-9. PubMed ID: 15193251
[TBL] [Abstract][Full Text] [Related]
49. 3'-Deoxy-3'-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose.
Yamamoto Y; Nishiyama Y; Ishikawa S; Gotoh M; Bandoh S; Kanaji N; Asakura M; Ohkawa M
J Comput Assist Tomogr; 2008; 32(3):432-7. PubMed ID: 18520552
[TBL] [Abstract][Full Text] [Related]
50. 18F-FDG PET of common enhancing malignant brain tumors.
Kosaka N; Tsuchida T; Uematsu H; Kimura H; Okazawa H; Itoh H
AJR Am J Roentgenol; 2008 Jun; 190(6):W365-9. PubMed ID: 18492879
[TBL] [Abstract][Full Text] [Related]
51. Are dual-phase 18F-FDG PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and loco-regional nodes?
Yen TC; Chang YC; Chan SC; Chang JT; Hsu CH; Lin KJ; Lin WJ; Fu YK; Ng SH
Eur J Nucl Med Mol Imaging; 2005 May; 32(5):541-8. PubMed ID: 15625603
[TBL] [Abstract][Full Text] [Related]
52. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
[TBL] [Abstract][Full Text] [Related]
53. Diagnostic usefulness of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography in recurrent brain tumor.
Hong IK; Kim JH; Ra YS; Kwon DH; Oh SJ; Kim JS
J Comput Assist Tomogr; 2011; 35(6):679-84. PubMed ID: 22082535
[TBL] [Abstract][Full Text] [Related]
54. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
55. Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET.
Kameyama R; Yamamoto Y; Izuishi K; Takebayashi R; Hagiike M; Murota M; Kaji M; Haba R; Nishiyama Y
Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):382-8. PubMed ID: 18985344
[TBL] [Abstract][Full Text] [Related]
56. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
57. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
58. Utility of 18F-FDG PET/CT uptake patterns in Waldeyer's ring for differentiating benign from malignant lesions in lateral pharyngeal recess of nasopharynx.
Chen YK; Su CT; Chi KH; Cheng RH; Wang SC; Hsu CH
J Nucl Med; 2007 Jan; 48(1):8-14. PubMed ID: 17204693
[TBL] [Abstract][Full Text] [Related]
59. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization.
Choi JY; Lee KS; Kim HJ; Shim YM; Kwon OJ; Park K; Baek CH; Chung JH; Lee KH; Kim BT
J Nucl Med; 2006 Apr; 47(4):609-15. PubMed ID: 16595494
[TBL] [Abstract][Full Text] [Related]
60. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer.
van Westreenen HL; Cobben DC; Jager PL; van Dullemen HM; Wesseling J; Elsinga PH; Plukker JT
J Nucl Med; 2005 Mar; 46(3):400-4. PubMed ID: 15750150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
